A Molecular Blueprint to Targeting ALK Gene Fusions in Glioblastoma.
Stephen C MackKelsey C BertrandPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Glioblastoma (GBM) is a heterogeneous brain tumor entity from infancy through adulthood. ALK gene fusions enriched in congenital and infant GBM have emerged as druggable driver alterations. Understanding the molecular basis and prevalence of ALK gene rearrangements will help define GBM patients that may benefit from ALK targeted therapy.
Keyphrases
- advanced non small cell lung cancer
- genome wide
- copy number
- end stage renal disease
- genome wide identification
- chronic kidney disease
- ejection fraction
- newly diagnosed
- risk factors
- prognostic factors
- peritoneal dialysis
- physical activity
- body mass index
- single molecule
- tyrosine kinase
- early life
- transcription factor